Wednesday, 16 November 2016, 09.00-16.30, Maastricht
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to the most lethal skin cancer. Indeed, epidemiologic data suggest that there are approximately 2500 new MCC cases per year within the EU; approximately 1000 of these patients will die from their disease. This high mortality rate is largely due to the fact that to date none of the currently available therapeutic interventions is able to improve overall survival of patients suffering from metastatic disease. Consequently, new therapeutic strategies are needed for metastatic MCC. Since several lines of evidence indicate the outstanding immunogenicity of MCC, immune modulating treatment strategies are particularly attractive.
International top speakers will present their latest research projects and results regarding on MCC.
The International Symposium focuses on:
- Update on the Epidemiology of MCC
- The carcinogenesis and biology of MCC
- Adaptive and innate immune responses to MCC
- Immune escape mechanisms of MCC
- Update on ongoing adjuvant and palliative immunotherapeutic trials in MCC
- Innovative interventions to boost immune responses to MCC
List of Speakers: Jürgen C. Becker Christopher Bichakjian James DeCaprio Nicole Fischer Rikke Lyngaa Axel zur Hausen Paul Nghiem Cathrin Ritter David Schrama Andreas Stang Masahiro Shuda
For registration, please send an email to firstname.lastname@example.org
Jürgen C. Becker: Information about the European Project IMMOMEC
IMMOMEC is a 5-year project to establish and investigate an innovative and effective immunotherapy for MCC. IMMOMEC will develop a rational immune therapeutic approach for treatment of patients with MCC that is based on the targeted delivery of interleukin-2 to the tumor microenvironment. However, IMMOMEC will not only provide a new therapeutic option for MCC patients, but will also establish the relevance of immune modulating strategies to treat solid cancers in general, establish and validate new tools to monitor patients receiving such therapies as well as compile prognostic and predictive biomarkers to individualize immune modulating therapies.
Please see more Information about the venue on: International Symposium